Vor Biopharma Inc. (VOR) Cash Flow Statement
Vor Biopharma Inc. (VOR) generated -$140.1M of operating cash flow over the twelve months to 2026-06-30, spent $726000 on capital expenditure and had free cash flow of -$140.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VORVor Biopharma Inc.Follow VOR — free
—
Price chart with a free account
- Market cap
- 1.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -69.1 | -85.1 | -100.3 | -99.7 | -142.7 | -140.1 | |
| Capital expenditure | 3.9 | 8.5 | 1.1 | 0.2 | 0.9 | -0.7 | |
| Free cash flow | -73.0 | -93.6 | -101.4 | -99.9 | -143.7 | -140.8 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Stock-based compensation | 4.3 | 10.7 | 13.4 | 9.8 | 18.9 | — |
USD millions · SEC XBRL
Vor Biopharma Inc. — questions
- What is Vor Biopharma Inc.'s operating cash flow?
- -$140.1M over the twelve months to 2026-06-30.
- How much does Vor Biopharma Inc. spend on capital expenditure?
- $726000 over the twelve months to 2026-06-30.
- What is Vor Biopharma Inc.'s free cash flow?
- -$140.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Vor Biopharma Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.